Open-label treatment with citalopram in patients with irritable bowel syndrome: A pilot study

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 7, Issue 4, 2005, Pages 162-166

  Masand, Prakash S ^a,e   Gupta, Sanjay ^b,c   Schwartz, Thomas L ^c   Virk, Subhdeep ^c   Hameed, Ahmad ^c   Kaplan, David S ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Olean General Hospital   (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^d Syracuse Gastroenterological Associates   (United States)

^e PsychCME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ABDOMINAL PAIN; ADULT; AGORAPHOBIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; COMORBIDITY; CONSTIPATION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPOSALIVATION; IRRITABLE COLON; MAJOR DEPRESSION; MALE; MENTAL DISEASE; PANIC; POSTTRAUMATIC STRESS DISORDER; REMISSION; SEDATION; SIDE EFFECT; SOCIAL PHOBIA; TREATMENT OUTCOME;

EID: 28944450410     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/pcc.v07n0404     Document Type: Article

References (41)

1. Lynn RB, Friedman LS. Irritable bowel syndrome. N Engl J Med 1993;329:1940-1945
2. Talley NJ, Zinsmeister AR, Van Dyke C, et al. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991; 101:927-934
3. Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987;92:1282-1284
4. Norton N. Functional bowel disorders survey. Participate 1997;6:1-3
5. Read NW, ed. The neurotic bowel: a paradigm for the irritable bowel syndrome. In: Read NW, ed. Irritable Bowel Syndrome, New Insights Into Pathophysiology. Oxford, UK: Blackwell Scientific Publications; 1991:3-4
6. Drossman DA, Li Z, Andrazzi E, et al. US householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact. Dig Dis Sci 1993;38:1569-1580
7. Drossman DA, McKee DC, Sandler RS, et al. Psychosocial factors in the irritable bowel syndrome: a multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology 1988;95:701-708
8. Mayer EA. Emerging disease model for functional gastrointestinal disorders. Am J Med 1999;107:12S-19S
9. Drossman DA, Sandler RS, McKee DC, et al. Bowel patterns among subjects not seeking health care: use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology 1982;83:529-534
10. Lydiard RB. Anxiety and the irritable bowel syndrome. Psychiatr Ann 1992;22:612-618
11. Whitehead WE, Crowell MD, Robinson JC, et al. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut 1992;33:825-830
12. Lydiard RB, Falsetti SA. Experience with anxiety and depression treatment studies: implications for designing irritable bowel syndrome clinical trials. Am J Med 1999;107:65S-73S
13. Masand PS, Kaplan DS, Gupta S, et al. Major depression and irritable bowel syndrome: is there a relationship? J Clin Psychiatry 1995;56: 363-367
14. Masand PS, Kaplan DS, Gupta S, et al. Irritable bowel syndrome and dysthymia: is there a relationship? Psychosomatics 1997;38:63-69
15. Masand PS, Kaplan DS, Gupta S, et al. Relationship between irritable bowel syndrome (IBS) and double depression (dysthymia plus major depression). Depression 1995/1996;3:303-308
16. Tollefson GD, Tollefson SL, Pederson M, et al. Comorbid irritable bowel syndrome in patients with generalized anxiety and major depression. Ann Clin Psychiatry 1991;3:215-222
17. Lydiard RB, Laraia MT, Howell EF, et al. Can panic disorder present as irritable bowel syndrome? J Clin Psychiatry 1986;47:470-473
18. Noyes R Jr, Cook B, Garvey M, et al. Reduction of gastrointestinal symptoms following treatment for panic disorder. Psychosomatics 1990;31:75-79
19. Kaplan DS, Masand PS, Gupta S. The relationship of irritable bowel syndrome (IBS) and panic disorder. Ann Clin Psychiatry 1996;8:81-88
20. Gupta S, Masand PS, Kaplan D, et al. The relationship between schizophrenia and irritable bowel syndrome (IBS). Schizophr Res 1997;23: 265-268
21. Masand PS, Sousou AJ, Gupta S, et al. Irritable bowel syndrome (IBS) and alcohol abuse or dependence. Am J Drug Alcohol Abuse 1998;24: 513-521
22. Read NW, Gwee KA. The importance of 5-hydroxytryptamine receptors in the gut. Pharmacol Ther 1994;62:159-173
23. Lucchelli A, Santagostino-Barbone MG, Barbieri A, et al. The interaction of antidepressant drugs with central and peripheral (enteric) 5-HT3 and 5-HT4 receptors. Br J Pharmacol 1995;114:1017-1025
24. Clouse RE. Antidepressants for functional gastrointestinal syndromes. Dig Dis Sci 1994;39:2352-2363
25. Thompson WG, Creed F, Drossman DA, et al. Functional bowel disease and functional abdominal pain. Gastroenterol Int 1992;5:75-91
26. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
27. Kobak KA, Greist JH, Jefferson JW, et al. Computerized assessment of depression and anxiety over the telephone using interactive voice response. MD Comput 1999;16:64-68
28. Kobak KA, Taylor LH, Dottl SL, et al. A computer-administered telephone interview to identify mental disorders. JAMA 1997;278:905-910
29. Mundt JC, Kobak KA, Taylor LV, et al. Administration of the Hamilton Depression Rating Scale using interactive voice response technology. MD Comput 1998;15:31-39
30. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002;122:1140-1156
31. Myren J, Groth H, Larssen SE, et al. The effect of trimipramine in patients with the irritable bowel syndrome: a double-blind study. Scand J Gastroenterol 1982;17:871-875
32. Myren J, Lovland B, Larssen SE, et al. A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol 1984;19:835-843
33. Clouse RE, Lustman PJ, Geisman RA, et al. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994;8:409-416
34. Masand PS, Gupta S, Schwartz TL, et al. Does a preexisting anxiety disorder predict response to paroxetine in irritable bowel syndrome? Psychosomatics 2002;43:451-455
35. Kirsch MA, Louie AK. Paroxetine and irritable bowel syndrome [case report]. Am J Psychiatry 2000;157:1523-1524
36. Emmanuel NP, Lydiard RB, Crawford M. Treatment of irritable bowel syndrome with fluvoxamine [letter]. Am J Psychiatry 1997;154:711-712
37. Thomas SG. Irritable bowel syndrome and mirtazapine [letter]. Am J Psychiatry 2000;157:1341-1342
38. Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003;1:219-228
39. Tabas G, Beaves M, Wang J, et al. Paroxetine to treat irritable bowel syndrome not responding to high fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004;99:914-920
40. Hyttel J, Bogeso KP, Perregaard J, et al. The pharmacologic effect of citalopram resides in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 1992;88:157-160
41. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press; 1996